Primary Dysmenorrhea Clinical Trial
— ASTRALOfficial title:
A National, Multicenter, Randomized, Double-blind, Double-dummy, Phase III, Crossover Study to Assess the Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea.
The purpose of this study if to evaluate the efficacy and safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea.
Status | Not yet recruiting |
Enrollment | 238 |
Est. completion date | January 30, 2027 |
Est. primary completion date | June 28, 2026 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 16 Years to 35 Years |
Eligibility | Inclusion Criteria: - Patient has given written informed consent to participate in the study prior to admission to the study; - Female patients aged between 16 and 35 years old, inclusive; - History of regular menstrual cycles, occuring between every 21 to 35 days; - Clinical history compatible with the diagnosis of primary dysmenorrhea; - Self-reported history of = 4 painful cycles, with moderate or severe menstrual cramps, in the six (06) months prior to selection for the study. Exclusion Criteria: - Diagnosis of secondary dysmenorrhea; - History of non-response to treatment with non-steroidal anti-inflammatory drugs (NSAIDs) to relieve menstrual cramps; - Onset of primary dysmenorrhea after starting to use oral contraceptives; - Use of oral contraceptives for < 3 months prior to study selection; - Use of an intrauterine device (IUD), hormonal implants or contraceptive injections in the last six (06) months; - Previous diagnosis or physical examination findings and/or clinical and/or surgical history that may indicate the presence of endometriosis, pelvic inflammatory disease, adenomyosis, mullerian duct malformation, uterine fibroma, cystic ovary and/or pelvic varicocele; - History of recurrent pelvic and/or lower abdominal pain outside the menstrual period; - Presence of known allergy or hypersensitivity to the components of the drugs used during the clinical trial; - History of hypersensitivity reactions, such as asthma attacks or other types of allergic reactions, to acetylsalicylic acid or other NSAIDs; - History or diagnosis of peptic/hemorrhagic ulcer; - History of gastrointestinal bleeding or perforation related to the use of NSAIDs; - Presence of compromised bone marrow function or diseases of the hematopoietic system; - Diagnosis of acute intermittent hepatic porphyria; - Diagnosis of congenital deficiency of glucose-6-phosphate dehydrogenase (G6PD); - Diagnosis of untreated angle-closure glaucoma; - Presence of mechanical stenosis in the gastrointestinal tract; - Diagnosis of megacolon and/or paralytic or obstructive ileus; - Diagnosis of myasthenia gravis; - Treatment with psychoactive drugs (such as, for example, antidepressants, antipsychotics, etc.) in the 30 days prior to selection for the study; - Participants with a history of alcohol or illicit drug use disorder in the last two (02) years; - Participants with a current medical history of cancer and/or cancer treatment in the last five (05) years; - Presence of any serious illness, at the discretion of the investigator; - Any finding of clinical observation (clinical/physical evaluation) or laboratory condition that is interpreted by the investigating physician as a risk to the participation of the research participant in the clinical trial or presence of uncontrolled chronic disease(s); - Participants who are pregnant, nursing or planning to become pregnant; - Disagreement with the use of a known effective barrier contraceptive method, unless using a stable oral contraceptive for three months or more (which must be maintained throughout the study), or surgically sterile or who expressly declare themselves exempt from risk of pregnancy for not exercising sexual practices or exercising them in a non-reproductive manner; - Participation in a clinical research protocol in the last 12 months (CNS Resolution 251, of August 7, 1997, item III, subitem J), unless the investigator judges that there may be a direct benefit to it; - Presence of any condition that, at the discretion of the investigator, makes the patient unfit to participate in the study. |
Country | Name | City | State |
---|---|---|---|
Brazil | Investigational Site | São Paulo | SP |
Lead Sponsor | Collaborator |
---|---|
EMS |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sum of Total Pain Relief (TOTPAR) over 0-4 hours post-dose. | Pain relief will be evaluated considering the Sum of Total Pain Relief (TOTPAR) over 0-4 hours post-dose. Pain relief will be evaluate using a Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). | 4 hours post-dose. | |
Secondary | Sum of Total Pain Relief (TOTPAR) over 0-8 hours post-dose. | Pain relief will be evaluated considering the Sum of Total Pain Relief (TOTPAR) over 0-8 hours post-dose. Pain relief will be evaluate using a Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). | 8 hours post-dose. | |
Secondary | Sum of Pain Intensity Difference (SPID) over 4 hours post-dose. | Sum of Pain Intensity Difference (SPID) over 4 hours post-dose. The pain intensity will be assessed using a Categorical 4-point scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain). | 4 hours post-dose. | |
Secondary | Sum of Pain Intensity Difference (SPID) over 8 hours post-dose. | Sum of Pain Intensity Difference (SPID) over 8 hours post-dose. The pain intensity will be assessed using a Categorical 4-point scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain). | 8 hours post-dose. | |
Secondary | Time to first intake of rescue medication. | Time between the first dose intake and the administration of a rescue medication. | Up to 8 hours post-dose. | |
Secondary | Patients who used rescue medication. | Number of participants who used rescue medication after the first drug intake. | Up to 8 hours post-dose. | |
Secondary | Doses of rescue medication used. | Number of rescue medication doses used in the first day of treatment. | Up to 8 hours post-dose. | |
Secondary | Number of additional drug intake. | Number of additional drug intake during the study period. | 3 days. | |
Secondary | Patients' Global Impression of Change (PGIC). | Patients' Global Impression of Change (PGIC) will be assessed after 8 hours post-dose or immediately before the intake of rescue medication. | 8 hours. | |
Secondary | Evaluate the safety of CDE100 association in the treatment of primary dysmenorrhea. | The safety will be evaluated considering the incidence of adverse events (AEs) reported during the study period. | Up to 175 days. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03608215 -
Neuromodulatary Efficacy of Transcranial Direct Current Stimulation in Severe Refractory Primary Dysmenorrhea
|
N/A | |
Completed |
NCT03594916 -
Efficacy of Transcranial Direct Current Stimulation for Severe Primary Dysmenorrhea
|
N/A | |
Not yet recruiting |
NCT04541134 -
Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea
|
Phase 3 | |
Completed |
NCT04083131 -
Sense of Coherence and Primary Dysmenorrhea in High School Girls in Finistere, France
|
||
Not yet recruiting |
NCT05448027 -
Low Versus High Intensity Laser Therapy on Primary Dysmenorrhea
|
N/A | |
Completed |
NCT04662814 -
Extracorporeal Shock Wave Therapy for Dysmenorrhea
|
N/A | |
Recruiting |
NCT05771753 -
Comparison of Core Stabilization and Dynamic Stretching Exercises in Primary Dysmenorrhea
|
N/A | |
Not yet recruiting |
NCT04665661 -
Aerobic Exercise for Primary Dysmenorrhea
|
N/A | |
Completed |
NCT03290066 -
Effectiveness of Kinesiotaping in Primary Dysmenorrhea
|
N/A | |
Completed |
NCT03593850 -
Music for Pain in Primary Dysmenorrhea
|
N/A | |
Completed |
NCT04235595 -
Comparison of the Effects of TENS and CTM on Primary Dysmenorrhea
|
N/A | |
Completed |
NCT05081869 -
Investigation of the Effect of Online Yoga Based Exercise Program on Women With Primary Dysmenorrhea
|
N/A | |
Not yet recruiting |
NCT06398990 -
The Effect of Cognitive Exercise Therapy Approach and Yoga in Adolescents With Dysmenorrhoea
|
N/A | |
Completed |
NCT02026206 -
Low-level Light Therapy for Primary Dysmenorrhea
|
Phase 3 | |
Completed |
NCT05686460 -
Effect of Hegu Point Ice Massage and Music in Dysmenorrhea
|
N/A | |
Not yet recruiting |
NCT06052722 -
The Relationship of Premenstrual Syndrome and Primary Dysmenorrhea With Severity of Temporomandibular Disorders
|
N/A | |
Completed |
NCT04119011 -
Probiotics in Women With Primary Dysmenorrhoea
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05938660 -
Effects of Acupressure at Sanyinjiao Point on Primary Dysmenorrhea Among University Students.
|
N/A | |
Completed |
NCT04856280 -
Kinesiological Taping and Aerobic Exercise in Women With Primary Dysmenorrhea:
|
N/A | |
Completed |
NCT02602522 -
Danshen-Jiang-Fu Granule Prepared by Danshen From Different Producing Areas for Primary Dysmenorrhea
|
Early Phase 1 |